BFEC
TEVA icon

Benjamin F. Edwards & Company’s Teva Pharmaceuticals TEVA Stock Holding History

Benjamin F. Edwards & Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$33K Sell
2,000
-500
-20% -$7.7K ﹤0.01% 1433
2024
Q1 		$35K Hold
2,500
– – ﹤0.01% 1400
2023
Q4 		$26K Hold
2,500
– – ﹤0.01% 1422
2023
Q3 		$26K Hold
2,500
– – ﹤0.01% 1202
2023
Q2 		$19K Hold
2,500
– – ﹤0.01% 1296
2023
Q1 		$22K Hold
2,500
– – ﹤0.01% 1261
2022
Q4 		$23K Hold
2,500
– – ﹤0.01% 1253
2022
Q3 		$20K Hold
2,500
– – ﹤0.01% 1266
2022
Q2 		$19K Hold
2,500
– – ﹤0.01% 1257
2022
Q1 		$23K Hold
2,500
– – ﹤0.01% 1207
2021
Q4 		$20K Hold
2,500
– – ﹤0.01% 1246
2021
Q3 		$24K Sell
2,500
-600
-19% -$5.62K ﹤0.01% 1192
2021
Q2 		$31K Buy
3,100
+2,500
+417% +$26.5K ﹤0.01% 1133
2021
Q1 		$7K Buy
+600
New +$6.88K ﹤0.01% 1445
2020
Q4 		– Sell
-250
Closed -$2K – 1736
2020
Q3 		$2K Hold
250
– – ﹤0.01% 1594
2020
Q2 		$3K Hold
250
– – ﹤0.01% 1545
2020
Q1 		$2K Hold
250
– – ﹤0.01% 1615
2019
Q4 		$2K Sell
250
-300
-55% -$2.68K ﹤0.01% 1790
2019
Q3 		$4K Sell
550
-200
-27% -$1.53K ﹤0.01% 1651
2019
Q2 		$7K Sell
750
-1,226
-62% -$14.8K ﹤0.01% 1534
2019
Q1 		$31K Sell
1,976
-7,805
-80% -$138K ﹤0.01% 1010
2018
Q4 		$151K Sell
9,781
-9,530
-49% -$195K 0.02% 546
2018
Q3 		$416K Sell
19,311
-3,050
-14% -$70.8K 0.04% 359
2018
Q2 		$544K Buy
22,361
+18,938
+553% +$386K 0.05% 310
2018
Q1 		$58K Buy
3,423
+1,098
+47% +$21.4K 0.01% 811
2017
Q4 		$44K Sell
2,325
-1,371
-37% -$20.6K ﹤0.01% 840
2017
Q3 		$65K Sell
3,696
-23,955
-87% -$539K 0.01% 708
2017
Q2 		$919K Buy
27,651
+13,581
+97% +$420K 0.12% 177
2017
Q1 		$451K Buy
14,070
+6,426
+84% +$219K 0.07% 271
2016
Q4 		$277K Buy
7,644
+951
+14% +$38K 0.05% 317
2016
Q3 		$308K Buy
6,693
+1,951
+41% +$102K 0.05% 284
2016
Q2 		$238K Buy
4,742
+597
+14% +$31.8K 0.05% 294
2016
Q1 		$222K Sell
4,145
-755
-15% -$44.3K 0.05% 290
2015
Q4 		$322K Buy
4,900
+118
+2% +$7.29K 0.07% 247
2015
Q3 		$270K Buy
4,782
+65
+1% +$4.21K 0.06% 266
2015
Q2 		$279K Buy
4,717
+498
+12% +$30.7K 0.06% 291
2015
Q1 		$263K Buy
4,219
+627
+17% +$36.5K 0.06% 288
2014
Q4 		$207K Buy
3,592
+1,002
+39% +$55.8K 0.05% 298
2014
Q3 		$139K Sell
2,590
-527
-17% -$27.9K 0.03% 350
2014
Q2 		$163K Sell
3,117
-37
-1% -$1.89K 0.04% 319
2014
Q1 		$167K Buy
3,154
+1,423
+82% +$65.8K 0.05% 300
2013
Q4 		$69K Sell
1,731
-2,300
-57% -$90.6K 0.02% 385
2013
Q3 		$152K Buy
4,031
+51
+1% +$1.99K 0.06% 260
2013
Q2 		$156K Buy
+3,980
New +$155K 0.06% 236

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Benjamin F. Edwards & Company's TEVA Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its Teva Pharmaceuticals (TEVA) stake by 20% in Q2 2024, selling an estimated $7.7K and leaving 2,000 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #1433.

Benjamin F. Edwards & Company first reported a position in TEVA in Q2 2013 and has held it in 44 quarters since. The position peaked at $919K in Q2 2017. 534 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Benjamin F. Edwards & Company held 2,000 shares of Teva Pharmaceuticals worth $33K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 500 Teva Pharmaceuticals shares in Q2 2024, an estimated $7.7K.
  • Teva Pharmaceuticals made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1433 holding.
  • Benjamin F. Edwards & Company first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Benjamin F. Edwards & Company's Teva Pharmaceuticals position peaked at $919K in Q2 2017.
  • 534 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.